Statement: Patients with Myocardial Infarction,percutaneous transluminal coronary angioplasty or Deep vein thrombosis within the last 2 - 6 months are eligible for the primary trial.
Primary_evidence: Inclusion Criteria:   Histologically proven advanced solid cancer for which curative therapy is not available (Part 1 only)   Histologically proven metastatic Her-2-negative breast cancer (Part 2 only)   Measurable disease by RECIST 1.1 criteria (Part 2 only)   Willing and able to consent for self to participate in study   Progressive or recurrent disease after prior systemic chemotherapy regimen   Age  18 years   ECOG performance status of 0 or 1   Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade  1 or baseline (except alopecia)   Adequate organ function Exclusion Criteria:   Prior treatment with more than one systemic chemotherapy regimen for metastatic disease.   Prior treatment with TRC105   History of hypersensitivity reaction to antimetabolite therapy   Receipt of an investigational agent within 28 days of starting study treatment   Prior surgery (including open biopsy), radiation therapy or systemic therapy within 28 days of starting study treatment   Minor surgical procedures within 14 days prior to first dose of TRC105   History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease   Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months   Uncontrolled chronic hypertension defined as systolic > 140 or diastolic > 90 despite optimal therapy   Past medical history of acquired or inherited coagulopathy including patients with known hereditary hemorrhagic telangiectasia   Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to first dose with TRC105   Cardiac dysrhythmias of NCI CTCAE Grade  2 within the last month   Hemorrhage within 28 days of starting study treatment   Unhealed wounds within 28 days of starting study treatment   History of peptic ulcer disease or gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment   Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness   Known active viral or nonviral hepatitis   History of hypersensitivity reaction to human or mouse antibody products   Lung cancer with central chest lesions   Pregnancy or breastfeeding